Alexander Hardy - 13 Mar 2026 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role: Chief Executive Officer, Director
Signature: /s/ Tae Sang Yoo, Attorney-in-Fact
Issuer symbol: BMRN
Transactions as of: 13 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Mar 2026, 20:43:06 UTC
Previous filing: 02 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hardy Alexander	Chief Executive Officer, Director	C/O BIOMARIN PHARMACEUTICAL INC, 770 LINDARO STREET, SAN RAFAEL	/s/ Tae Sang Yoo, Attorney-in-Fact	17 Mar 2026	0002001910

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BMRN	Common Stock	Tax liability		-2,941	-1.8%	$58.51^*	156,447	13 Mar 2026	Direct
transaction	BMRN	Common Stock	Award		+62,440	+40%	$0.000000^*	218,887	16 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BMRN	Stock Option (Right to Buy Common Stock)	Award		+89,200		$0.000000^*	89,200	16 Mar 2026	Common Stock	89,200	$57.43	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units granted March 16, 2026. Price not applicable.
F2	Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.